MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Prostate Cancer Treatment and Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,880 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,880 works in the cohort · of 4,299,418page 53 of 78

Labels cover 13 of 3,880 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,880 of 3,880 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).
Bertrand Tombal, Yohann Loriot, Fred Saad, Sandrine Marréaud, Laurence Collette, Silke Gillessen
2018· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affvenueunlabeled
Prostate cancer, ESMO 2016
Bobby Shayegan
2016· review· en· Canadian Urological Association Journal· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
fundno affno abstractunlabeled
Trithorax Genes in Prostate Cancer
Pier‐Luc Clermont, Francesco Crea, D. Cheryl
2013· book-chapter· en· InTech eBooks· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
The Landscape of Prostate Tumour Methylation
Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Jieun Oh, Paul C. Boutros
2025· preprint· en· bioRxiv (Cold Spring Harbor Laboratory)· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Prostate-Specific Antigen (PSA)
Marc A. Kowalkouski, Heather Honoré Goltz, Stacey L. Hart, David Latini
2013· book-chapter· en· Medicine
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About